Innovent Biologics Teams Up with Pfizer for $10.5B Deal; Goldman Sachs Reiterates Buy and Raises Price Target

Overview

This research report primarily analyzes the global strategic collaboration announced by Innovent Biologics (1801.HK) on May 29, 2026, with Pfizer (PFE). The transaction has a total potential value of $10.5 billion, covering 12 early-stage oncology projects, marking a key step in Innovent's 'Vision 2030' globalization vision. Goldman Sachs believes that this transaction not only brings significant near-term cash inflows but also optimizes risk sharing and capital efficiency through a complex cooperation structure, reflecting deep MNC recognition of Chinese biotech companies' early innovation capabilities. Based on this positive news, Goldman Sachs has upgraded its profit forecasts and price targets, reiterating its Buy rating.

Core views

Transaction Structure and Economic Terms: The collaboration between Innovent Biologics and Pfizer covers 12 early-stage oncology projects using three differentiated cooperation models with four projects each: global licensing, licensing outside Greater China, and joint development/joint commercialization (with Innovent retaining rights in Greater China). Financial terms include a $650 million upfront payment, up to $9.85 billion in milestone payments, double-digit royalties on sales, and profit-sharing mechanisms for certain projects. Innovent is responsible for discovery and early clinical development (up to Phase I), while Pfizer handles late-stage global development and commercialization. This refined structural design aims to balance short-term cash monetization with long-term upside收益。 Validation of Globalization Strategy: This is Innovent's second systematic, multi-project early-stage innovation integration deal with a top-tier multinational after its February deal with Eli Lilly (LLY). Unlike traditional single-asset outbound licenses, this transaction focuses on novel ADC and multi-specific antibody platforms, further strengthening market confidence in Innovent's accumulated platform Know-how (e.g., multi-antibodies like IBI363, IBI3003, and ADCs like IBI343/IBI3020). Additionally, the addition of four joint development projects brings Innovent's total to five such projects, allowing it to retain meaningful economic benefits and strategic participation globally. Industry Trend Signals: This transaction continues the trend of Chinese biopharmaceutical companies transitioning from 'asset exporters' to 'long-term innovation partners.' Global pharmaceutical giants are increasingly collaborating with Chinese entities at the discovery/early clinical stages, packaging multiple early-stage projects or platform capabilities (e.g., CSPC/AZ, Hengrui/BMS/GSK cases). This reflects both recognition of the breadth and depth of the Chinese early-stage innovation drug pool and affirmation of Chinese biotech companies' rapid Proof-of-Concept (POC) capabilities. Valuation and Earnings Forecast Update: Considering license revenue increases from the PFE transaction and the prior LLY transaction (assuming accounting treatment similar to the Takeda deal), Goldman Sachs has raised 2026E-2028E EPS forecasts from RMB 1.42/3.11/4.19 yuan to RMB 2.09/3.34/4.35 yuan accordingly. Correspondingly, the 12-month price target based on the DCF model was raised from HK$105.94 to HK$107.04. Institutional investors believe the current market-implied Weighted Average Cost of Capital (WACC) of 12% only reflects the value of de-risked indications, failing to fully account for strong revenue growth and pipeline potential, suggesting the stock is undervalued.

Analysis framework

This report adopts a framework combining event-driven analysis with fundamental valuation. First, by dissecting the complex BD deal structure (three cooperation models, two new modalities, and a combination of existing and new projects), it evaluates the comprehensive impact on cash flow, risk exposure, and long-term strategic value, rather than simply summing upfront payments and milestone amounts. Second, the case is placed within an industry macro context; by comparing recent series of platform-type transactions between Chinese Biotechs and MNCS, it extracts the logic of the industry paradigm shift from 'asset export' to 'ecosystem co-building.' Finally, at the valuation level, a risk-adjusted DCF model is used to focus on the expectation gap between the market-implied WACC and the company's actual pipeline value, thereby arguing for the attractiveness of the current valuation. This methodology emphasizes deep mining of transaction 'quality' and 'structural dividends,' rather than just focusing on the headline deal size.

Methodology notes

• Valuation MethodDCF Cash Flow Discount

  Risk-adjusted DCF Valuation

  When calculating the price target using the DCF model, the research report does not simply predict future cash flows but introduces risk adjustment factors, discounting expected cash flows according to success probabilities at different stages of drug development to more realistically reflect the uncertainty of early pipelines. It also compares the market-implied WACC with company fundamentals to determine if the valuation fully reflects pipeline value.

• Competition and Strategy FrameworkValue chain analysis

  Division of Labor and Benefit Distribution in BD Transactions

  By analyzing 'who is responsible for which segment' (e.g., Innovent for discovery/Phase I, Pfizer for late-stage/commercialization) and 'who gets what money' (upfront payment, milestones, royalties, profit sharing), the report assesses the position and bargaining power of both parties in the value chain. This analysis helps understand why certain deals bring higher long-term strategic value beyond short-term cash.

• Industry/Industrial Analysis FrameworkUpstream, Midstream, Downstream Transmission in Industry Chain

  Evolution of Chinese Biotech's Role in the Global Innovation Chain

  The report elevates a single company's BD transaction to the industry chain level, pointing out that Chinese Biotechs are transforming from pure 'upstream asset suppliers' to 'long-term partners' in the global innovation ecosystem. This role change means moving from one-time sales to platform-based, systemic deep binding, which is a sign of increased industry maturity.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Innovent Biologics (1801.HK)

  Direct beneficiary, receiving $650 million upfront payment and long-term milestone proceeds, validating globalization capabilities

  Strengths

  Deep immuno-oncology pipeline, novel ADC and multi-antibody platforms recognized by MNDS, strong commercialization capabilities, and experience in deep cooperation with partners like Eli Lilly

  Weaknesses

  Intensifying competition in PD-1/L1 markets, uncertainty in approval timelines for key candidate drugs

  Comparison

  Compared to traditional single-asset exports, Innovent retains more global rights and economic returns through multi-project, multi-model cooperation

  Risks

  Risk of R&D project failure, potential restrictions on off-label use, regulatory limitations due to safety issues

Key data

• Total Transaction Value$10.5 BillionIncludes $650 million upfront payment and up to $9.85 billion in milestone payments
• Number of Collaborative Projects12Covers global licensing, licensing outside Greater China, and joint development, with four projects in each category
• 2026E EPS Forecast (New)RMB 2.09Significantly upgraded from original forecast of 1.42, reflecting increased license revenue
• 2027E EPS Forecast (New)RMB 3.34Upgraded from original forecast of 3.11
• 2028E EPS Forecast (New)RMB 4.35Upgraded from original forecast of 4.19
• 12-Month Price TargetHK$107.04Upgraded from previous HK$105.94, based on DCF model
• Current Stock PriceHK$74.85Closing price as of May 28, 2026
• Implied Upside43.0%Calculated based on price target and current stock price

Impact & implications

For Innovent Biologics, this transaction is not only a major financial positive but also a strategic milestone. It demonstrates that the company's early R&D platform possesses global competitiveness, capable of attracting top-tier MNDS for deep binding, thereby reducing reliance solely on the domestic market. For the Chinese biopharmaceutical industry, this transaction further consolidates the trend of 'platform-type BD' becoming mainstream, signaling that companies with differentiated technology platforms and rapid POC capabilities will receive more global premiums. For investors, attention should be paid to subsequent milestone achievements and clinical progress of joint development projects, as these will be key catalysts to verify the long-term value of the transaction.

Risks

• Continued intensification of competition in China's PD-1/L1 market
• Uncertainty in approval timelines for key candidate drugs
• Potential restrictions on off-label use if safety issues arise
• Risk of R&D project failure

What to watch

• Clinical progress and milestone achievement status of joint development models in PFE cooperative projects
• Subsequent data readouts for novel ADC and multi-specific antibody platforms
• Actual realization degree of company 2026-2028 EPS forecasts
• Impact of changes in the China market PD-1 competitive landscape on the company's core products